{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:11:37Z","timestamp":1793985097724,"version":"4.8.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"CorEvitas, LLC"},{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s13555-023-01028-5","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T16:02:04Z","timestamp":1695830524000},"page":"2753-2768","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Durability of Near-Complete Skin Clearance in Patients with Psoriasis Using Systemic Biologic Therapies: Real-World Evidence from the CorEvitas Psoriasis Registry"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct02707341","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Robert R.","family":"McLean","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam P.","family":"Sima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silky","family":"Beaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Eckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"McClung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Spitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Stark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"issue":"2","key":"1028_CR1","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/bjd.12372","volume":"169","author":"O Van Cranenburgh","year":"2013","unstructured":"Van Cranenburgh O, De Korte J, Sprangers M, De Rie M, Smets E. Satisfaction with treatment among patients with psoriasis: a web-based survey study. Br J Dermatol. 2013;169(2):398\u2013405.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1028_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7525-4-35","volume":"4","author":"MJ Bhosle","year":"2006","unstructured":"Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;4(1):1\u20137.","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"1028_CR3","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/jdv.12817","volume":"29","author":"L Puig","year":"2015","unstructured":"Puig L. PASI 90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol. 2015;29(4):645\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1028_CR4","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/bjd.20568","volume":"185","author":"K Reich","year":"2021","unstructured":"Reich K, Gordon K, Strober B, et al. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol. 2021;185(6):1146\u201359.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1028_CR5","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.jaad.2019.11.040","volume":"82","author":"K Reich","year":"2020","unstructured":"Reich K, Griffiths CE, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020;82(4):936\u201345.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1028_CR6","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1111\/bjd.20716","volume":"185","author":"I Kotb","year":"2021","unstructured":"Kotb I. Evidence for the long-term efficacy and safety of guselkumab. Br J Dermatol. 2021;185(6):1087\u20138.","journal-title":"Br J Dermatol"},{"issue":"12","key":"1028_CR7","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1016\/j.jid.2019.05.016","volume":"139","author":"KB Gordon","year":"2019","unstructured":"Gordon KB, Armstrong AW, Foley P, et al. Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study. J Invest Dermatol. 2019;139(12):2437\u201346.e1.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1028_CR8","doi-asserted-by":"publisher","first-page":"31e1\u2013e15","DOI":"10.1016\/j.jaad.2006.07.017","volume":"56","author":"A Menter","year":"2007","unstructured":"Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31e1\u2013e15.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1028_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jaad.2017.10.012","volume":"78","author":"B Strober","year":"2018","unstructured":"Strober B, Karki C, Mason M, et al. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the Corrona Psoriasis Registry. J Am Acad Dermatol. 2018;78(2):323\u201332.","journal-title":"J Am Acad Dermatol"},{"key":"1028_CR10","unstructured":"National Psoriasis Foundation. CorEvitas (formerly Corrona) Psoriasis Patient Registry; 2015 [updated 2022]. https:\/\/www.psoriasis.org\/corevitas-psoriasis-patient-registry\/. Accessed 29 June 2022."},{"key":"1028_CR11","unstructured":"Clinicaltrials.gov. The Corrona Psoriasis (PSO) Registry: National Library of Medicine; 2016 [updated 2022]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02707341. Accessed 29 June 2022."},{"issue":"1","key":"1028_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/pds.3891","volume":"25","author":"Public Policy Committee International Society of Pharmacoepidemiology","year":"2016","unstructured":"Public Policy Committee International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf. 2016;25(1):2\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1028_CR13","first-page":"1","volume":"2","author":"International Council for Harmonisation","year":"2015","unstructured":"International Council for Harmonisation. Integrated addendum to ICH E6 (R1): guideline for good clinical practice E6 (R2). Curr Step. 2015;2:1\u201360.","journal-title":"Curr Step"},{"issue":"7","key":"1028_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1526-5900(03)00716-8","volume":"4","author":"MP Jensen","year":"2003","unstructured":"Jensen MP, Chen C, Brugger AM. Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain. J Pain. 2003;4(7):407\u201314.","journal-title":"J Pain"},{"issue":"6\u20137","key":"1028_CR15","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2340\/00015555-2642","volume":"97","author":"A Reich","year":"2017","unstructured":"Reich A, Chatzigeorkidis E, Zeidler C, et al. Tailoring the cut-off values of the visual analogue scale and numeric rating scale in itch assessment. Acta Derm Venereol. 2017;97(6\u20137):759\u201360.","journal-title":"Acta Derm Venereol"},{"issue":"345","key":"1028_CR16","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/01621459.1974.10480146","volume":"69","author":"BW Turnbull","year":"1974","unstructured":"Turnbull BW. Nonparametric estimation of a survivorship function with doubly censored data. J Am Stat Assoc. 1974;69(345):169\u201373.","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"1028_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/bjd.19544","volume":"184","author":"M Schmitt-Egenolf","year":"2021","unstructured":"Schmitt-Egenolf M. Complete skin clearance and beyond. Br J Dermatol. 2021;184(1):3.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1028_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaad.2016.03.026","volume":"75","author":"B Strober","year":"2016","unstructured":"Strober B, Papp KA, Lebwohl M, et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol. 2016;75(1):77\u201382.e7.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1028_CR19","first-page":"1086","volume":"14","author":"IF Manalo","year":"2015","unstructured":"Manalo IF, Gilbert KE, Wu JJ. Time to raise the bar to psoriasis area severity index 90 and 100. J Drugs Dermatol. 2015;14(10):1086\u20138.","journal-title":"J Drugs Dermatol"},{"key":"1028_CR20","volume":"35","author":"L Mastorino","year":"2022","unstructured":"Mastorino L, Siliquini N, Avallone G, et al. Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real-life study. Dermatol Ther. 2022;35:e15670.","journal-title":"Dermatol Ther"},{"issue":"10","key":"1028_CR21","doi-asserted-by":"publisher","first-page":"adv00579","DOI":"10.2340\/actadv.v101.351","volume":"101","author":"CW Schwarz","year":"2021","unstructured":"Schwarz CW, Loft N, Rasmussen MK, et al. Predictors of response to biologics in patients with moderate-to-severe psoriasis: a Danish Nationwide Cohort Study. Acta Derm Venereol. 2021;101(10):adv00579.","journal-title":"Acta Derm Venereol"},{"issue":"11","key":"1028_CR22","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1038\/jid.2015.208","volume":"135","author":"RB Warren","year":"2015","unstructured":"Warren RB, Smith CH, Yiu ZZN, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632\u201340.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"1028_CR23","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jid.2017.09.044","volume":"138","author":"IYK Iskandar","year":"2018","unstructured":"Iskandar IYK, Warren RB, Lunt M, et al. Differential drug survival of second-line biologic therapies in patients with psoriasis: observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2018;138(4):775\u201384.","journal-title":"J Invest Dermatol"},{"issue":"7","key":"1028_CR24","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/jdv.13611","volume":"30","author":"A Menter","year":"2016","unstructured":"Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30(7):1148\u201358.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01028-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-01028-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01028-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T10:12:27Z","timestamp":1698487947000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-01028-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1028"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-01028-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]},"assertion":[{"value":"30 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Robert R. McLean, Adam P. Sima, Eric A. Jones, Thomas Eckmann, Rebecca L. Spitzer: Employees of CorEvitas; Silky Beaty, Robert Low, Laura McClung, Jeffrey Stark: Employees and shareholders of UCB Pharma; April Armstrong: Has served as a research investigator and\/or scientific advisor to AbbVie, Almirall, Arcutis, ASLAN, Boehringer Ingelheim, BMS, Dermavant, Dermira, Eli Lilly, EPI, Incyte, Janssen, LEO Pharma, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sun Pharma, Sanofi, and UCB Pharma; CorEvitas, LLC, has been supported through contracted subscriptions in the last two years by AbbVie, Amgen, Arena, Boehringer Ingelheim, BMS, Celgene, Chugai, Eli Lilly, Genentech, Gilead, GSK, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB Pharma. The CorEvitas Psoriasis Registry was developed in collaboration with the National Psoriasis Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was performed following the guidelines for Good Pharmacoepidemiology Practice [] and in accordance with the current version of the applicable regulatory and International Council for Harmonisation Good Clinical Practice requirements [], the ethical principles that have their origin in the principles of the Declaration of Helsinki, and the local laws of the countries involved. All patients provided written informed consent for participation in the registry. All participating investigators were required to obtain full board approval for conducting non-interventional research involving human subjects with a limited dataset. Sponsor (CorEvitas, LLC) approval and continuing review was obtained through a central IRB (IntegReview, protocol number is Corrona-PSO-500). For academic investigative sites that did not receive a waiver to use the central IRB, full board approval was obtained from the respective governing IRBs, and documentation of approval was submitted to CorEvitas, LLC, prior to the initiation of any study procedures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}